Literature DB >> 18798074

Can the lack of HSP90alpha protein in brain normal tissue and cell lines, rationalise it as a possible therapeutic target for gliomas?

Amal Shervington1, Nichola Cruickshanks, Robert Lea, Gareth Roberts, Tim Dawson, Leroy Shervington.   

Abstract

Despite studies suggesting a role for HSP90alpha in tumorigenesis, there are no reports as to its expression in normal human brain tissue. In this study, the expression of HSP90alpha was evaluated in both cell lines (3 gliomas and 2 controls) and brain tissue specimens of 10 patients (8 gliomas and 2 normal brain tissues). No HSP90alpha protein was detected in either normal cell lines or normal brain tissue. However, 8/8 glioma tissues and 3/3 glioma cell lines did express HSP90alpha. These findings provide a rationale for targeting HSP90alpha protein as a therapeutic candidate for glioma.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18798074     DOI: 10.1080/07357900802087259

Source DB:  PubMed          Journal:  Cancer Invest        ISSN: 0735-7907            Impact factor:   2.176


  4 in total

Review 1.  The development and characterization of protein-based stationary phases for studying drug-protein and protein-protein interactions.

Authors:  Mitesh Sanghvi; Ruin Moaddel; Irving W Wainer
Journal:  J Chromatogr A       Date:  2011-05-27       Impact factor: 4.759

2.  Can RNAi-mediated hsp90α knockdown in combination with 17-AAG be a therapy for glioma?

Authors:  Adi Mehta; Amal Shervington; John Howl; Sarah Jones; Leroy Shervington
Journal:  FEBS Open Bio       Date:  2013-06-20       Impact factor: 2.693

3.  Identifying Reliable Diagnostic/Predictive Biomarkers for Rheumatoid Arthritis.

Authors:  Leroy Shervington; Ashish Darekar; Murassa Shaikh; Roshini Mathews; Amal Shervington
Journal:  Biomark Insights       Date:  2018-09-24

4.  A novel therapeutic strategy for the treatment of glioma, combining chemical and molecular targeting of hsp90a.

Authors:  Adi Mehta; Leroy Shervington; Chinmay Munje; Amal Shervington
Journal:  Cancers (Basel)       Date:  2011-12-08       Impact factor: 6.639

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.